search button
Open Access

Severe cytopenia during adjuvant chemotherapy for early breast cancer in a patient with idiopathic CD4+ lymphocytopenia

  • Authors:
    • Kaito Mimura
    • Akihiko Shimomura
    • Koji Watanabe
    • Hanako Koda
    • Kanako Nakayama
    • Dai Kitagawa
    • Chikako Shimizu

  • View Affiliations

  • Published online on: July 4, 2023     https://doi.org/10.3892/ol.2023.13943
  • Article Number: 357

  • Copyright: © Mimura et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Idiopathic CD4+ lymphocytopenia (ICL) is a rare immunodeficiency disorder characterized by decreased CD4+ T‑cell counts in the absence of human immunodeficiency virus (HIV) infection. Similar to HIV infection, ICL is commonly associated with acquired immunodeficiency syndrome‑defining cancers, such as Kaposi sarcoma, non‑Hodgkin lymphoma and cervical cancer; however, the presentation of breast cancer in a patient with ICL is rare. The current study presented the clinical course of a patient with early breast cancer and ICL. Following surgery, the patient underwent adjuvant chemotherapy comprising doxorubicin plus cyclophosphamide, followed by paclitaxel. The patient's immunodeficiency status required the prophylactic administration of clarithromycin, trimethoprim‑sulfamethoxazole and valganciclovir. Throughout the course of chemotherapy, the patient experienced severe complications of febrile neutropenia, anemia, neutropenia and thrombocytopenia, and was eventually forced to discontinue anticancer chemotherapy, as the relative dose intensity (RDI) could not be maintained. Similar hematological complications and reduced RDI, leading to worse outcomes, are also common in patients with HIV infection receiving chemotherapy, suggesting that CD4+ T cell‑deficient patients are prone to developing cytopenia during chemotherapy. The present study demonstrates the importance of further data accumulation in patients with ICL with cancer and the development of a methodology for maintaining the RDI.
View Figures
View References

Related Articles

Journal Cover

August-2023
Volume 26 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Mimura K, Shimomura A, Watanabe K, Koda H, Nakayama K, Kitagawa D and Shimizu C: Severe cytopenia during adjuvant chemotherapy for early breast cancer in a patient with idiopathic CD4+ lymphocytopenia. Oncol Lett 26: 357, 2023
APA
Mimura, K., Shimomura, A., Watanabe, K., Koda, H., Nakayama, K., Kitagawa, D., & Shimizu, C. (2023). Severe cytopenia during adjuvant chemotherapy for early breast cancer in a patient with idiopathic CD4+ lymphocytopenia. Oncology Letters, 26, 357. https://doi.org/10.3892/ol.2023.13943
MLA
Mimura, K., Shimomura, A., Watanabe, K., Koda, H., Nakayama, K., Kitagawa, D., Shimizu, C."Severe cytopenia during adjuvant chemotherapy for early breast cancer in a patient with idiopathic CD4+ lymphocytopenia". Oncology Letters 26.2 (2023): 357.
Chicago
Mimura, K., Shimomura, A., Watanabe, K., Koda, H., Nakayama, K., Kitagawa, D., Shimizu, C."Severe cytopenia during adjuvant chemotherapy for early breast cancer in a patient with idiopathic CD4+ lymphocytopenia". Oncology Letters 26, no. 2 (2023): 357. https://doi.org/10.3892/ol.2023.13943